[rayiner]

There is no economic system in which the skilled educated labor necessary to create these drugs can be compensated by what money you can get from a relatively small number of poor people with s rare disease. You cut $300,000 per year for treatment to $30,000 per year, and this company is operating at huge losses. And it's still not affordable to even normal people.